Tolufazepam is a 1-alkylsulfonylaryl-1,4-benzodiazepine derivative. It exhibited a competitive antagonism of 3H-diazepam binding in the cerebellum, cerebrum and submaxillary gland. Tolufazepam showed anticonvulsant and anxiolytic activity in animal models – it was very potent in preventing convulsions elicited by pentylenetetrazol. This anticonvulsant action was suppressed by previous administration of Ro 15-1788. Tolufazepam was also active in inhibiting suppressive behavior in the test of Vogel.

Tolpiprazole is a tranquilliser.

MK-0941 is selective, allosteric glucokinase activator (GKA) that activates glucokinase (hexokinase subtype IV) with greater selectivity than over different hexokinase isoforms. In chronic oral toxicity studies in animals with MK-0941, cataracts were observed in rats and dogs at drug exposures of 3 and 1.5 times, respectively, the maximum predicted human exposure based on doses planned for further clinical development. No cataracts were observed in either species at drug exposures equal to the maximum predicted human exposure. In patients receiving stable-dose insulin glargine, the glucokinase activator MK-0941 led to improvements in glycemic control that were not sustained. MK-0941 was associated with an increased incidence of hypoglycemia and elevations in triglycerides and blood pressure.

Fenaftic acid is a choleretic agent.

FENFLUMIZOLE, an imidazole derivative, is a nonsteroidal, anti-inflammatory agent. It is a potent cyclooxygenase inhibitor with anti-phlogistic potency equalling that of indomethacin.

Levisoprenaline (l-isoproterenol) is beta1- and beta2-adrenoreceptor agonist. In Japan, continuous inhalation of levisoprenaline is a recommended treatment for pediatric patients with acute severe exacerbation. Compared with salbutamol, l-isoproterenol reduced modified pulmonary index score more rapidly. But in most countries do not recommend continuous inhalation of l-isoproterenol to treat pediatric patients with acute severe exacerbation of asthma due to worsening asthma control. Levisoprenaline was used to cause experimental chronic heart failure in rats.

Piconol (2-Pyridinemethanol) is a pyridylalcohol devivative with hypoglycemic activity.

FIBRACILLIN is a semisynthetic antibacterial agent.

IRINDALONE is an antihypertensive agent. It is a serotonin receptor antagonist with weak alpha 1-adrenoceptor blocking properties.

Pirinixil is an ethanolamine derivative of Wy-14,643 [4-chloro-6-(2,3-xylidino)-2-pyrimidinythio]acetic acid. It is the hypolipidemic agent of low toxicity. It has been reported to increase high density lipoprotein cholesterol levels in experimental animals. Pirinixil increased plasma cholesterol levels significantly without affecting plasma triglycerides. Pirinixil exerted a powerful antilipolytic activity against epinephrine, ACTH, nicotine and cold exposure. It is a potent inducer of liver peroxisones and of mitochondrial carmitine acetyltransferase. Pirinixil was developed treatment of hyperlipidemias and atherosclerosis. Pirinixil can increase generation of ROS, leading to DNA damage and p53 phosphorylation, which, in turn, induces the activation of Bax, release of cytochrome-c from mitochondria and activation of caspases, culminating in rat hepatoma FaO cell death.